MedTrace Logo

Topic Ketorolac Added to Panphotocoagulation in Proliferative Diabetic Retinopathy

NCT00907114 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2015-03-20

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of topic ketorolac in treatment for center point thickness secondary to panphotocoagulation in proliferative diabetic retinopathy.

Conditions

  • Proliferative Diabetic Retinopathy
  • Macular Edema

Interventions

DRUG

Ketorolac tromethamine

Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation

DRUG

Polivynilic alcohol

Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation

Sponsors & Collaborators

  • Hospital Juarez de Mexico

    lead OTHER_GOV

Principal Investigators

  • Virgilio Lima Gomez, MD, MSc · Hospital Juarez de Mexico

  • Dulce M Razo Blanco Hernandez, MD · Hospital Juarez de Mexico

  • Juan Asbun Bojalil, MD, PhD · Hospital Juarez de Mexico

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00907114 on ClinicalTrials.gov